Quick Answer
vTv Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2025.
vTv Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$1.02M | $0.00 -100.0% |
$2.02M -49.6% |
$4.00M -37.6% |
$6.41M +132.1% |
| Revenue (ASC 606) | $0.00 -100.0% |
$1.02M | $0.00 -100.0% |
$2.02M -49.6% |
$4.00M -37.6% |
$6.41M +132.1% |
| Net Income | -$26.97M -46.1% |
-$18.46M +8.8% |
-$20.25M -5.7% |
-$19.16M -47.6% |
-$12.99M -52.8% |
-$8.50M +34.8% |
| Total Assets | $89.90M +134.9% |
$38.27M +247.3% |
$11.02M -66.9% |
$33.24M +30.5% |
$25.47M +72.2% |
$14.79M +59.6% |
| Cash and Equivalents | $88.93M +142.0% |
$36.75M +289.0% |
$9.45M -22.1% |
$12.13M -9.6% |
$13.41M +133.4% |
$5.75M +223.4% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $64.44M +428.2% |
$12.20M +149.4% |
-$24.68M -129.8% |
-$10.74M -10.3% |
-$9.74M +87.8% |
-$80.10M -63.4% |
| R&D Expense | $17.86M +54.7% |
$11.55M -15.1% |
$13.60M +10.0% |
$12.36M -7.3% |
$13.32M +21.0% |
$11.02M -27.1% |
| Operating Income | -$32.81M -35.7% |
-$24.18M +5.2% |
-$25.50M -13.1% |
-$22.54M -4.1% |
-$21.66M -82.8% |
-$11.85M +43.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$8.70M | -81.9% | -43.9% |
| Total Assets | September 30, 2025 | $99.49M | +130.5% | +276.2% |
| Cash and Equivalents | September 30, 2025 | $98.50M | +137.0% | +280.0% |
| Long-Term Debt | December 31, 2014 | $2.11M | — | — |
| Stockholders Equity | September 30, 2025 | $70.54M | +370.0% | +2454.1% |
| R&D Expense | September 30, 2025 | $7.02M | +117.7% | +71.1% |
| Operating Income | September 30, 2025 | -$10.70M | -64.4% | -38.6% |
| Shares Outstanding | September 30, 2015 | 0 | — | — |
- vTv Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- vTv Therapeutics Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- vTv Therapeutics Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- vTv Therapeutics Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- vTv Therapeutics Inc. reported Net Income of -$26.97 million for fiscal year 2025.
- vTv Therapeutics Inc. showed a decrease of -46.1% in Net Income compared to the prior fiscal year.
- vTv Therapeutics Inc. reported Total Assets of $89.90 million for fiscal year 2025.
- vTv Therapeutics Inc. showed an increase of +134.9% in Total Assets compared to the prior fiscal year.
- vTv Therapeutics Inc. reported Cash and Equivalents of $88.93 million for fiscal year 2025.
- vTv Therapeutics Inc. showed an increase of +142.0% in Cash and Equivalents compared to the prior fiscal year.
- vTv Therapeutics Inc. reported Long-Term Debt of $2.11 million for fiscal year 2014.
- vTv Therapeutics Inc. reported Stockholders Equity of $64.44 million for fiscal year 2025.
- vTv Therapeutics Inc. showed an increase of +428.2% in Stockholders Equity compared to the prior fiscal year.
- vTv Therapeutics Inc. reported R&D Expense of $17.86 million for fiscal year 2025.
- vTv Therapeutics Inc. showed an increase of +54.7% in R&D Expense compared to the prior fiscal year.
- vTv Therapeutics Inc. reported Operating Income of -$32.81 million for fiscal year 2025.
- vTv Therapeutics Inc. showed a decrease of -35.7% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: